Drug Trial Radar · NCT06891040
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Apr 28, 2025
Primary completion
Oct 31, 2025
Study completion Nov 4, 2025
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, vehicle controlled phase II clinical study
Conditions
- Atopic Dermatitis
Interventions
VC005 Placebo groupDrug
VC005 Placebo group with Local topical application
VC005 groupsDrug
VC005 group with Local topical application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in EASI(Eczema area and severity index) from baselineTime frame: 8 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences Hospital of Skin Disease
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.